Catalog No.: PC-61370Not For Human Use, Lab Use Only.
CT-707 (Conteltinib) is a novel multikinase inhibitor targeting FAK (IC50=1.6 nM), ALK and Pyk2, exerts synergistic antitumor effects against hepatocellular carcinoma in vitro and in vivo.
CT-707 (Conteltinib) is a novel multikinase inhibitor targeting FAK (IC50=1.6 nM), ALK and Pyk2, exerts synergistic antitumor effects against hepatocellular carcinoma in vitro and in vivo.
CT-707 (Conteltinib) effectively inhibits the activation of FAK induced by cabozantinib.
CT-707 (Conteltinib) displays potent activities in arresting cancer cell growth, promoting cell detachment, and decreasing wound healing, also exhibits potent anticancer activities in vivo, inhibits tumor growth and metastasis in T47D, Karpas299, and 4T1 xenograft models.
